Dr Garderet speaks with ecancer at the 16th International Myeloma Workshop about the outcome of third salvage autologous stem cell transplantation in multiple myeloma.
Autologous stem cell transplantation remains a standard treatment for younger patients with multiple myeloma.
With the aid of new drugs, the patients live longer and third salvage ASCT is an increasingly used option.
However, the outcome of third salvage autologous stem cell transplantation has not yet been analysed.
Dr Garderet also spoke with ecancer about his highlights of the conference here.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.